AnaptysBio, Inc. (NASDAQ:ANAB) Stock Has Consensus Target Price of $77.79 According to Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have received an average rating of “Moderate Buy” from the seventeen research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $77.79.

A number of analysts have weighed in on ANAB shares. Wolfe Research reiterated an “outperform” rating and issued a $78.00 price target on shares of AnaptysBio in a research report on Monday, August 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of AnaptysBio in a report on Tuesday, September 22nd. HC Wainwright restated a “buy” rating and issued a $95.00 target price on shares of AnaptysBio in a research note on Tuesday, September 22nd. Scotiabank lowered shares of AnaptysBio to a “hold” rating and set a $70.00 target price on the stock. in a report on Tuesday, August 25th. Finally, JPMorgan Chase & Co. dropped their target price on shares of AnaptysBio from $70.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, September 30th.

AnaptysBio Stock Performance

Shares of AnaptysBio stock opened at $48.10 on Friday. The firm’s 50-day simple moving average is $52.87 and its 200-day simple moving average is $57.20. AnaptysBio has a twelve month low of $20.18 and a twelve month high of $72.36. The firm has a market cap of $1.44 billion, a P/E ratio of 319.60 and a beta of 0.76.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Monday, September 21st. The biotechnology company reported $5.11 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $5.57. The company had revenue of $27.49 million for the quarter, compared to analyst estimates of $14.06 million. AnaptysBio had a return on equity of 112.00% and a net margin of 82.37%. During the same period in the prior year, the company posted ($1.30) EPS. On average, equities analysts forecast that AnaptysBio will post -1.30 earnings per share for the current fiscal year.

Insider Buying and Selling

In other AnaptysBio news, Director Hollings Renton sold 5,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $49.87, for a total transaction of $249,350.00. Following the sale, the director directly owned 10,995 shares of the company’s stock, valued at approximately $548,320.65. This represents a 31.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 31.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ANAB. Sterling Capital Management LLC grew its position in AnaptysBio by 847.8% during the 3rd quarter. Sterling Capital Management LLC now owns 654 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 585 shares during the last quarter. Kings Path Partners LLC acquired a new stake in AnaptysBio during the 3rd quarter valued at $188,000. Robeco Institutional Asset Management B.V. acquired a new stake in AnaptysBio during the 3rd quarter valued at $852,000. State of Alaska Department of Revenue bought a new position in AnaptysBio in the 3rd quarter valued at $85,000. Finally, Farther Finance Advisors LLC raised its position in AnaptysBio by 2,440.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 10,033 shares of the biotechnology company’s stock valued at $504,000 after purchasing an additional 9,638 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for immune-mediated diseases. The company uses its proprietary antibody discovery and engineering platform to identify therapeutics designed to modulate immune-system pathways involved in inflammation and autoimmune disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 immune checkpoint pathway, and imsidolimab, an investigational antibody targeting the interleukin-36 receptor.